TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 412-418

  Selmi, Abdelkader ^a,b   de Saint Jean, Maud ^a,b   Jallas, Anne Catherine ^c,d   Garin, Elisabeth ^c,d   Hogarty, Michael D ^e   Bénard, Jean ^f   Puisieux, Alain ^a,b,c   Marabelle, Aurélien ^a,b,c,d   Valsesia Wittmann, Sandrine ^a,c,d  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c CENTRE LÉON BÉRARD   (France)

^d Lyon   (France)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

MYC; MYCN; Transcriptional regulation neuroblastoma; TWIST1

Indexed keywords

MYC PROTEIN; MYC PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DNA SEQUENCE; E BOX ELEMENT; GENE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MYCN GENE; NEUROBLASTOMA; ONCOGENE MYC; PROMOTER REGION; TRANSCRIPTION REGULATION; TWIST1 GENE; UPREGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; TRANSFECTION; TWIST TRANSCRIPTION FACTOR;

EID: 84920576922     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.056     Document Type: Article

References (42)

1. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
2. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984, 224:1121-1124.
3. Brodeur G.M. Molecular basis for heterogeneity in human neuroblastomas. Eur. J. Cancer 1995, 31A:505-510.
4. Norris M.D., Burkhart C.A., Marshall G.M., Weiss W.A., Haber M. Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med. Pediatr. Oncol 2000, 35:585-589.
5. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997, 16:2985.
6. Hogarty M.D. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett 2003, 197:173-179.
7. Lutz W., Stöhr M., Schürmann J., Wenzel A., Löhr A., Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996, 13:803-812.
8. Wakamatsu Y., Watanabe Y., Nakamura H., Kondoh H. Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation. Development 1997, 124:1953-1962.
9. Kenney A.M., Widlund H.R., Rowitch D.H. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 2004, 131:217-228.
10. Oliver T.G., Grasfeder L.L., Carroll A.L., Kaiser C., Gillingham C.L., Lin S.M., et al. Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7331-7336.
11. Schuldiner O., Benvenisty N. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene 2001, 20:4984-4994.
12. Chambéry D., Mohseni-Zadeh S., de Gallé B., Babajko S. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line. Cancer Res 1999, 59:2898-2902.
13. Hiyama E., Hiyama K., Yokoyama T., Fukuba I., Yamaoka H., Shay J.W., et al. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma. Clin. Cancer Res 1999, 5:601-609.
14. Slack A., Chen Z., Tonelli R., Pule M., Hunt L., Pession A., et al. The P53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. PNAS 2005, 102:731-736.
15. Gupta A., Williams B.R.G., Hanash S.M., Rawwas J. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma. Cancer Res 2006, 66:8100-8108.
16. Koppen A., Ait-Aissa R., Hopman S., Koster J., Haneveld F., Versteeg R., et al. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. Cancer Lett 2007, 256:218-228.
17. Cotterman R., Knoepfler P.S. N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b. PLoS ONE 2009, 4.
18. Valsesia-Wittmann S., Magdeleine M., Dupasquier S., Garin E., Jallas A.-C., Combaret V., et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004, 6:625-630.
19. Leptin M., Grunewald B. Cell shape changes during gastrulation in Drosophila. Development 1990, 110:73-84.
20. Bialek P., Kern B., Yang X., Schrock M., Sosic D., Hong N., et al. A twist code determines the onset of osteoblast differentiation. Dev. Cell 2004, 6:423-435.
21. Blackwood E.M., Eisenman R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991, 251:1211-1217.
22. Blackwell T.K., Huang J., Ma A., Kretzner L., Alt F.W., Eisenman R.N., et al. Binding of myc proteins to canonical and noncanonical DNA sequences. Mol. Cell. Biol 1993, 13:5216-5224.
23. Ansieau S., Bastid J., Doreau A., Morel A.-P., Bouchet B.P., Thomas C., et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008, 14:79-89.
24. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999, 13:2207-2217.
25. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
26. Kwok W.K., Ling M.-T., Lee T.-W., Lau T.C.M., Zhou C., Zhang X., et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005, 65:5153-5162.
27. Mironchik Y., Winnard P.T., Vesuna F., Kato Y., Wildes F., Pathak A.P., et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 2005, 65:10801-10809.
28. Puisieux A., Valsesia-Wittmann S., Ansieau S. A twist for survival and cancer progression. Br. J. Cancer 2006, 94:13-17.
29. Li Q.-Q., Xu J.-D., Wang W.-J., Cao X.-X., Chen Q., Tang F., et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer Res 2009, 15:2657-2665.
30. Mikheeva S.A., Mikheev A.M., Petit A., Beyer R., Oxford R.G., Khorasani L., et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol. Cancer 2010, 9:194.
31. Vesuna F., Lisok A., Kimble B., Raman V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 2009, 11:1318-1328.
32. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. RESEARCH0034.
33. Liu X., Mazanek P., Dam V., Wang Q., Zhao H., Guo R., et al. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 2008, 27:1478-1488.
34. Bello-Fernandez C., Packham G., Cleveland J.L. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:7804-7808.
35. Barrett J.F., Lee L.A., Dang C.V. Stimulation of Myc transactivation by the TATA binding protein in promoter-reporter assays. BMC Biochem 2005, 6:7. 10.1186/1471-2091-6-7.
36. Breit S., Schwab M. Suppression of MYC by high expression of NMYC in human neuroblastoma cells. J. Neurosci. Res 1989, 24:21-28.
37. Westermann F., Muth D., Benner A., Bauer T., Henrich K.-O., Oberthuer A., et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008, 9:R150. 10.1186/gb-2008-9-10-r150.
38. Manohar C.F., Short M.L., Nguyen A., Nguyen N.N., Chagnovich D., Yang Q., et al. HuD, a neuronal-specific RNA-binding protein, increases the in vivo stability of MYCN RNA. J. Biol. Chem 2002, 277:1967-1973.
39. Qin Q., Xu Y., He T., Qin C., Xu J. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res 2011, 10.1038/cr.2011.144.
40. Lutz W., Fulda S., Jeremias I., Debatin K.M., Schwab M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998, 17:339-346.
41. Edsjö A., Nilsson H., Vandesompele J., Karlsson J., Pattyn F., Culp L.A., et al. Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. Lab. Invest 2004, 84:406-417.
42. Khan M.A., Chen H.C., Zhang D., Fu J. Twist: a molecular target in cancer therapeutics. Tumor Biol 2013, 34(5):2497-2506.